The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

BACKGROUND: Mechanisms by which Smac mimetics (SMs) interact with proteasome inhibitors (e.g., bortezomib) are largely unknown, particularly in multiple myeloma (MM), a disease in which bortezomib represents a mainstay of therapy. METHODS: Interactions between the clinically relevant IAP (inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Liang, Zhang, Yu, Leng, Yun, Dai, Yun, Kmieciak, Maciej, Kramer, Lora, Sharma, Kanika, Wang, Yan, Craun, William, Grant, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407248/
https://www.ncbi.nlm.nih.gov/pubmed/30845975
http://dx.doi.org/10.1186/s13045-019-0713-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407248/
https://www.ncbi.nlm.nih.gov/pubmed/30845975
http://dx.doi.org/10.1186/s13045-019-0713-x

Ejemplares similares